QPPV.COM KNOWLEDGE ASSESSMENT

Sotrovimab: Classification, Mechanism, EU Authorisation History and Pharmacovigilance

Test your understanding of the concepts covered by Sotrovimab: Classification, Mechanism, EU Authorisation History and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 When reviewing aggregate safety data across different periods of sotrovimab use, which approach best addresses potential changes in the data context?

Pool all reports without regard to time because the product was unchanged. Consider calendar period, circulating variants, treatment access, disease severity, patient risk profile, and changes in testing or reporting. Exclude reports with missing variant information so that only fully characterised cases remain. Interpret any increase in reports as an increase in drug-related risk.

Question 2 of 10 Which information set is most useful for characterising a historical suspected infusion reaction?

Only the patient's age and the final outcome The symptom chronology, infusion details, clinical observations, intervention, response and whether the infusion was restarted or stopped Only the batch number and the presumed causal relationship The variant name alone, even if the infection course is unavailable

Question 3 of 10 A reviewer concludes that a patient received no clinical benefit because symptoms worsened after treatment. What additional reasoning is most appropriate before attributing the outcome to loss of sotrovimab activity against a variant?

Assume a resistant variant because the antibody targets a viral protein. Consider treatment timing, disease progression, immune status, co-interventions and the quality of variant data. Use the outcome alone as proof of reduced in-vitro susceptibility. Disregard the patient's oxygen requirement because it is unrelated to treatment context.

Question 4 of 10 Which description best characterises sotrovimab's pharmacological classification and target?

A human IgG1 monoclonal antibody directed against an epitope in the SARS-CoV-2 spike protein's receptor-binding region A small-molecule inhibitor that blocks the SARS-CoV-2 main protease A humanised antibody that binds the host ACE2 receptor to prevent viral attachment A recombinant vaccine antigen that stimulates active immunity against SARS-CoV-2

Question 5 of 10 Which conclusion is most appropriate when an aggregate review finds more reports of poor outcomes during a later variant period?

The reports prove that the later variant caused treatment failure. The finding warrants contextual review, but report counts alone do not establish incidence, comparative effectiveness or variant causation. The finding proves the medicine became less safe during that period. The reports should be excluded because treatment occurred during a different calendar period.

Question 6 of 10 Which statement best describes the QPPV's role in relation to the safety information discussed in the article?

The QPPV should ensure relevant safety information informs system oversight, without replacing clinical judgement. The QPPV must determine the clinical diagnosis in place of the treating clinician. The QPPV's oversight responsibilities end when a product's authorisation is withdrawn. The QPPV should disregard historical cases because they cannot affect pharmacovigilance records.

Question 7 of 10 A patient develops hypoxia several days after sotrovimab administration. Which assessment principle is most appropriate?

Hypoxia proves a delayed infusion reaction because it followed administration. COVID-19 progression and other clinical explanations should be considered alongside a possible treatment-related event. The event cannot be reportable because hypoxia is a manifestation of COVID-19. The event should be assigned to reduced variant susceptibility without further investigation.

Question 8 of 10 Which statement best distinguishes historical product use from a current treatment recommendation?

A description of the former indication remains a recommendation as long as the medicine appears in case reports. The former indication explains use during the authorised period but does not recommend use now that the EU authorisation has been withdrawn. Historical product information is irrelevant once the authorisation ends. A withdrawn product should be described as currently authorised if it was authorised when a case occurred.

Question 9 of 10 Which documentation weakness is most likely to impair assessment of a suspected infusion-related event?

Recording symptoms without their chronology in relation to the infusion Recording the patient's weight when it is relevant to the historical label Including the outcome and any treatment given Noting whether the infusion was stopped or restarted

Question 10 of 10 How should the 18 February 2026 EU withdrawal of Xevudy be represented in a regulatory or pharmacovigilance record?

As a safety-based suspension imposed by EMA that proves the product had an unacceptable benefit–risk balance As a withdrawal at the marketing authorisation holder's request for commercial reasons, not described as safety-based As a temporary interruption that left the EU authorisation in force As a withdrawal caused by a confirmed increase in anaphylaxis reports

QPPV.com

Sotrovimab: Classification, Mechanism, EU Authorisation History and Pharmacovigilance

Cookie Settings